Smith, Moore & Co. Mirati Therapeutics, Inc. Transaction History

Smith, Moore & Co.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $117,479 - $266,130	3,000 New	3,000 $201,000
Q1 2022 May 12, 2022	SELL	$75.82 - $150.97 $151,640 - $301,940	-2,000 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$132.01 - $190.29 $66,005 - $95,145	500 Added 33.33%	2,000 $293,000
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $198,195 - $266,175	1,500 New	1,500 $265,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Smith, Moore & Co., based on Form 13F filings with the SEC.

Stay updated on Smith, Moore & Co. with notifications on news.